Abstract：【Objective】To study the clinical effect of minimally invasive interventional therapy on hepatocellular carcinoma and its influence on T cell immune function in patients.【Methods】A total of 40 liver cancer patients who treated by transcatheter arterial chemoembolization and 40 patients with liver cancer who treated by radiofrequency ablation in our hospital between January 2014 and December 2017 were categorized group A and group B, respectively. The clinical data of the two groups were analyzed retrospectively, and the clinical efficacy, T cell immune function index, postoperative complications, liver function index, postoperative pain score and quality of life score were compared between the two groups.【Results】In terms of clinical efficacy, there was no significant difference in objective remission rate and total effective rate between the two groups( P > 0.05). Compared to that in group A, the serum ALT level in group B was significantly higher ( P < 0.05). After operation, the CD3+ and CD4/CD8 of the two groups were lower than those before the operation( P < 0.05), while the CD3+ and CD4/CD8 in group B were higher than those in the group A ( P < 0.05). There was no significant difference in the incidence of postoperative complications between the two groups ( P > 0.05). The scores at 8h, 12h, 24h and 48h after operation in group B were lower than those in group A ( P < 0.05). After operation, the quality of life scores in both groups were significantly higher than those before the operation ( P < 0.05), but that in group B was higher than that in group A ( P < 0.05).【Conclusion】The use of radiofrequency ablation in the treatment of liver cancer patients can reduce the interference of interventional therapy on the immune function of T cells and liver function as much as possible on the premise of interventional therapy, which is beneficial to alleviating postoperative pain and improving the quality of life.
夷泽君, 乌建平. 微创介入治疗肝癌对患者T细胞免疫功能的影响[J]. 医学临床研究, 2018, 35(7): 1301-1303.
YI Ze-jun, WU Jian-ping. Changes of T Cell Immune Function in Patients with Liver Cancer Treated by Minimally Invasive Interventional Therap. JOURNAL OF CLINICAL RESEARCH, 2018, 35(7): 1301-1303.
[1] Farinati F, Vanin V, Giacomin A, et al.BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group[J].Liver Int,2015,35(1):223-231. [2] 梁博,王国平.微创介入疗法对肝癌患者 T细胞免疫功能的影响分析[J].实用癌症杂志,2015,30(4):488-490. [3] 赵鹏,郑加生,张洪海等.肝动脉导管化疗栓塞联合 CT 引导精准微波消融治疗原发性肝癌的疗效及影响因素[J].中华肿瘤杂志,2016,38(2):138-145. [4] 董安楠,李旺,吴方明等.细胞因子诱导杀伤细胞免疫联合微创介入治疗早期肝癌的长期临床疗效观察[J].中华医学杂志,2015,95(33):2668-2672. [5] 袁宏军,刘凤永,李鑫等.肝动脉化疗栓塞联合局部消融治疗大肝癌的现状和趋势[J].中华肝胆外科杂志,2017,23(10):712-716. [6] 张百红,岳红云.实体瘤疗效评价标准简介[J].国际肿瘤学杂志,2016,43(11):845-847. [7] Hiraoka A, Ishimaru Y, Kawasaki H,et al.Tumor markers AFP, AFP-L3, and DCP in hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J].Oncology,2015,89(3):167-174. [8] 杨沛华,丁红兵,周观林等.不同微创介入治疗原发性肝癌对机体T细胞免疫功能的作用[J].当代医学,2016,22(29):79-80. [9] Chao Y, Chung Y, Han G, et al.The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial[J].Int J Cancer,2015,136(6):1458-1467. [10] 李高峰,章硕.介入联合放射治疗与介入治疗原发性大/巨大肝癌的比较[J].中国微创外科杂志,2018,18(1):23-25. [11] Joskin J,de Baere T,Auperin A,et al. Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor[J].Cardiov Int Radiol,2015,38(2):372-380. [12] 宗迎迎,徐浩,许伟等.经肝动脉化疗栓塞联合经皮微波消融序贯治疗早期肝癌的疗效及预后影响因素[J].介入放射学杂志,2015,24(3):210-214. [13] Hung YL, Wang CC.Hepatobiliary and pancreatic: gas-forming liver abscess caused by salmonella after transcatheter arterial chemoembolization for hepatocellular carcinoma[J].J Gastroenterol Hepatol,2015,30(10):1449-1449. [14] 赵中伟,纪建松,邵国良等.肝动脉化疗栓塞联合射频消融治疗包膜下肝癌的疗效和安全性[J].中华放射学杂志,2016,50(5):380-383. [15] 叶甲舟,谢志波,白涛等.术后辅助肝动脉化疗栓塞对存在早期复发危险肝癌患者的必要性[J].中华肝胆外科杂志,2016,22(4):217-222.
2018, Vol. 35 
